Opexa Therapeutics to discuss on personalized medicine for treatment of MS

Opexa Therapeutics, Inc. (NASDAQ: OPXA), a company developing a novel T-cell therapy for multiple sclerosis (MS), announced today that the company will participate in a panel discussion on Personalized Medicine for the Treatment of Multiple Sclerosis on April 7, 2010.

Invited panelists are:

  • Robert Darnell, M.D., Ph.D, Investigator, Howard Hughes Medical Institute Heilbrunn Cancer Professor and Senior Physician, The Rockefeller University
  • Neil K. Warma, President & Chief Executive Officer of Opexa Therapeutics, Inc.
  • Dawn McGuire, M.D., Chair Clinical Advisory Board, Opexa Therapeutics, Inc.

The event will be moderated by Elemer Piros, Ph.D, Senior Biotechnology Analyst at Rodman & Renshaw, LLC.

The presentation will take place at the Rodman & Renshaw Offices (1251 Avenue of the Americas, 20th Floor, New York, NY 10020) at 4:30PM ET on April 7, 2010. 

Source:

Opexa Therapeutics, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Western diet accelerates endometriosis growth and disrupts gut health